A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab pre-treated patients with Her2-positive metastatic breast cancer - E-Vita -
J. Bischoff
◽
J. Barinoff
◽
C. Mundhenke
◽
D. Bauerschlag
◽
S.D. Costa
◽
...
H Wildiers
◽
K Tryfonidis
◽
L dal Lago
◽
P Vuylsteke
◽
G Curigliano
◽
...
SH Sim
◽
IH Park
◽
KH Jung
◽
S-B Kim
◽
J-H Ahn
◽
...
Edith A Perez
◽
Sara A Hurvitz
◽
Lukas C Amler
◽
Kirsten E Mundt
◽
Vivian Ng
◽
...
GV Bianchi
◽
J Kocsis
◽
L Dirix
◽
Y Torigoe
◽
D Lalla
◽
...
2002 ◽
Vol 38
(11)
◽
pp. S95
2017 ◽
Vol 28
◽
pp. v106-v107
◽
P. Villagrasa Gonzalez
◽
A. Prat
◽
M. Oliveira
◽
L. de la Pena
◽
X. Gonzalez
◽
...
L. Petruzelka
◽
V. Ganju
◽
P.F. Conte
◽
N. Tubiana-Mathieu
◽
F. Majois
◽
...
2018 ◽
Vol 29
(1)
◽
pp. 154-161
◽
H.S. Han
◽
V. Diéras
◽
M. Robson
◽
M. Palácová
◽
P.K. Marcom
◽
...
1993 ◽
Vol 4
(1)
◽
pp. 45-50
◽
K. Mross
◽
C. Bohn
◽
L. Edler
◽
W. Jonat
◽
W. Queisser
◽
...
2018 ◽
Vol 29
◽
pp. viii120
◽
H. Bonnefoi
◽
C. Levy
◽
G. MacGrogan
◽
T. Grellety
◽
B. Asselain
◽
...
Close
Export Citation Format
Close
Share Document
Close